Head and Neck
11
3
4
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 11 trials
100.0%
+13.4% vs benchmark
9%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (11)
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Immediate Neuromuscular Responses of the Obliquus Capitis Inferior Following Upper Cervical Manual Therapy
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Identification of Nerves Using Fluorescein Sodium
4DryField PH and Head and Neck Operations.
Value of Geriatric Screening to Predict Postoperative Morbidity for Head and Neck Cancer
A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer
Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
The Use of Prostaglandin E1 in Head and Neck Microsurgery